Inclusion Criteria -End stage renal disease and on hemodialysis for 90 days prior to screening. Exclusion Criteria -Study subjects on an active clinical trial that uses an investigational medication, age < 18years old, thrombocytopenia (platelet count < 60,000), abnormal liver function tests (3 times upper limit of normal transaminases), have a known sensitivity to any of the active ingredients, patients currently taking vitamin C > 500 mg per day, vitamin E supplements > 60 mg (90 IU) per day, vitamin D supplements > 300 IU (7.5µg) per day, ferritin < 100, Tsat < 10%, pregnant subjects, sexually active female subjects who are of childbearing potential and not willing to use an acceptable form of contraceptive. Demographics: A total of 25 hemodialysis subjects signed informed consent and were enrolled into the study after meeting all inclusion and no exclusion criteria. This population consisted of one African American male, one Hispanic male, 13 Caucasian females, and 10 Caucasian males. The average age of the study subjects was 65 years old with an average BMI of 36.69. The hemodialysis accesses of enrolled subjects consisted of 16 arteriovenous fistulas, 3 arteriovenous grafts, and 6 central venous catheters. General Study Design: Open label, non-blinded, non-randomized single site study lasting 12 weeks (excluding screening and baseline laboratory periods). Multiple laboratory parameters were monitored on a routine basis to determine the efficacy of the multivitamin. Description of Drug: The ingredients of the nutraceutical MV-ONE ® are formulated in capsules, which include Cholecalciferol 1500 IU, Gamma-Tocopherol at 300mg and Alpha Lipoic Acid 600mg given once in the morning with food (two capsules were self administered to provide the total daily amount). Ethical Considerations: All study procedures were performed using good clinical research practices that abided by the regulations of the FDA and ICH guidelines. Adverse Events: Adverse events were recorded, assessed for severity and reported to the proper authorities if applicable. Study data points were removed from analyses if adverse event was related to physiological abnormality and observed to be a significant outlier. Compliance: Self drug administration compliance was expected to be ≥ 85%. Non-compliant subject laboratory values were excluded from the analyses. Dialysis Facility Xenobiotic Parameters: The study subject xenobiotic requirements for iv erythropoietin stimulating agents ( 
Introduction And Overview
As of October 2010, the National Institutes of Health had estimated that 23 million American's have been diagnosed with chronic kidney disease (CKD), and it is evident that this population continues to segue from special to a significant one in the world. It is predicted that these negative health consequences could be onset due to prolonged hyperphysiological stress hormone and oxidative stress factor synthesis and secretion (2, 5, 10). The influences of physiological and oxidative stressor transduction signals induced by hyper-secretion and/or production of cortisol, cytokines, tumor necrosis factors, reactive oxidative species and other stress and inflammatory responses have been suggested to alter the homeostasis of normal bone physiology and erythrocyte production at both genetic and non-genetic levels (1, 3, 5, 10), and this could possibly be a major influence aiding in the generation of the progressive negative health states observed in ESRD patients requiring dialysis.
The studies presented here hypothesized that providing dialysis patients with an additive active vitamin D xenobiotic in combination with a mixture of antioxidant nutraceutical therapies could assist in treatment of secondary hyperparathyroidism, and also, target inflammation to improve dialysis patient's anemic parameters. The study paradigm consisted of 25 male and female hemodialysis patients that gave informed consent and met all criteria outlined in the materials and methods section. This study was designed to be an open label, non-blinded, non-randomized single site protocol with a treatment period that consisted of 12 weeks. Due to studies that suggest that vitamin D itself is a potent anti-inflammatory agent (11), it is possible that the antiinflammatory effects of MV-ONE ® require a longer monitored treatment period to revel a philological steady state effect for the parameters of increased vitamin D levels to initiate treatment of secondary hyperparathyroidism, which might only be produced after a decreased inflammatory state is reached by this antioxidant nutraceutical. Especially since 12 to 16 weeks is common for a steady state to be reached by nuclear drug actions according to common pharmacology practice (9). Overall, these studies present a strong case that the MV-ONE ® antioxidant nutraceutical is physiologically beneficial and also, a cost effective and adjuvant for dialysis patients that require consistent treatment for secondary hyperparathyroidism and anemia. However, further multicenter studies with larger subject numbers and longer treatment periods are needed to fully determine the therapeutic potential of MV-ONE ® as an additive therapy.
•MV-ONE ® increases active vitamin D blood levels in hemodialysis patients identifying it's efficacious ability to potentiate treatment for secondary hyperparathyroidism.
•MV-ONE ® decreases the ESA therapy required in hemodialysis patients identifying it's benefits aiding in the treatment of CKD-and hemodialysis-induced anemia.
•Approximately 85% patients reported overall improved well-being after taking MV-ONE ® . Quality of life questionnaires should be used in future studies.
•The antioxidative properties of MV-ONE ® therapy may be a useful cost-effective adjuvant in an increasingly challenging clinical environment. 
Figure 3. A) The 12 week administration of the novel renal multivitamin antioxidant nutraceutical MV-ONE ® caused a non-significant 4% mean decrease in the uric acid levels of hemodialysis study subjects (red) compared to the mean controls (black). B) The administration of MV-ONE ® did not significantly alter c-reactive protein levels observed in hemodialysis study subjects (red) compared to controls (black), although there was a 10% increase in mean values. Importantly, CRP is still an exploratory indicator of inflammation and longer studies with a larger study population are required to validate results. C) The administration of MV-ONE ® did not significantly alter cholesterol levels observed in hemodialysis study subjects (red) compared to controls (black)
.
